Literature DB >> 33035656

Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers.

Kuo Chen1, Pengwei Lu2, Narasimha M Beeraka3, Olga A Sukocheva4, SubbaRao V Madhunapantula3, Junqi Liu5, Mikhail Y Sinelnikov6, Vladimir N Nikolenko7, Kirill V Bulygin7, Liudmila M Mikhaleva8, Igor V Reshetov9, Yuanting Gu2, Jin Zhang9, Yu Cao9, Siva G Somasundaram10, Cecil E Kirkland10, Ruitai Fan11, Gjumrakch Aliev12.   

Abstract

Epigenetic regulation of mitochondrial DNA (mtDNA) is an emerging and fast-developing field of research. Compared to regulation of nucler DNA, mechanisms of mtDNA epigenetic regulation (mitoepigenetics) remain less investigated. However, mitochondrial signaling directs various vital intracellular processes including aerobic respiration, apoptosis, cell proliferation and survival, nucleic acid synthesis, and oxidative stress. The later process and associated mismanagement of reactive oxygen species (ROS) cascade were associated with cancer progression. It has been demonstrated that cancer cells contain ROS/oxidative stress-mediated defects in mtDNA repair system and mitochondrial nucleoid protection. Furthermore, mtDNA is vulnerable to damage caused by somatic mutations, resulting in the dysfunction of the mitochondrial respiratory chain and energy production, which fosters further generation of ROS and promotes oncogenicity. Mitochondrial proteins are encoded by the collective mitochondrial genome that comprises both nuclear and mitochondrial genomes coupled by crosstalk. Recent reports determined the defects in the collective mitochondrial genome that are conducive to breast cancer initiation and progression. Mutational damage to mtDNA, as well as its overproliferation and deletions, were reported to alter the nuclear epigenetic landscape. Unbalanced mitoepigenetics and adverse regulation of oxidative phosphorylation (OXPHOS) can efficiently facilitate cancer cell survival. Accordingly, several mitochondria-targeting therapeutic agents (biguanides, OXPHOS inhibitors, vitamin-E analogues, and antibiotic bedaquiline) were suggested for future clinical trials in breast cancer patients. However, crosstalk mechanisms between altered mitoepigenetics and cancer-associated mtDNA mutations remain largely unclear. Hence, mtDNA mutations and epigenetic modifications could be considered as potential molecular markers for early diagnosis and targeted therapy of breast cancer. This review discusses the role of mitoepigenetic regulation in cancer cells and potential employment of mtDNA modifications as novel anti-cancer targets.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Breast cancer; Mitochondria; Mitoepigenetics; Oxidative stress; mtDNA

Mesh:

Substances:

Year:  2020        PMID: 33035656     DOI: 10.1016/j.semcancer.2020.09.012

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  48 in total

Review 1.  Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts.

Authors:  Dietrich Averbeck; Claire Rodriguez-Lafrasse
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

Review 2.  Breast Cancer Genomics: Primary and Most Common Metastases.

Authors:  Caroline Bennett; Caleb Carroll; Cooper Wright; Barbara Awad; Jeong Mi Park; Meagan Farmer; Elizabeth Bryce Brown; Alexis Heatherly; Stefanie Woodard
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

3.  Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.

Authors:  Kuo Chen; Jin Zhang; Narasimha M Beeraka; Chengyun Tang; Yulia V Babayeva; Mikhail Y Sinelnikov; Xinliang Zhang; Jiacheng Zhang; Junqi Liu; Igor V Reshetov; Olga A Sukocheva; Pengwei Lu; Ruitai Fan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

Review 4.  Immunological Landscape of HER-2 Positive Breast Cancer.

Authors:  Santiago Moragon; Cristina Hernando; Maria Teresa Martinez-Martinez; Marta Tapia; Belen Ortega-Morillo; Ana Lluch; Begoña Bermejo; Juan Miguel Cejalvo
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 5.  Artemisinin-type drugs for the treatment of hematological malignancies.

Authors:  R I Mancuso; M A Foglio; S T Olalla Saad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

Review 6.  The crosstalk between HIFs and mitochondrial dysfunctions in cancer development.

Authors:  Xingting Bao; Jinhua Zhang; Guomin Huang; Junfang Yan; Caipeng Xu; Zhihui Dou; Chao Sun; Hong Zhang
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

Review 7.  Antioxidants Targeting Mitochondrial Oxidative Stress: Promising Neuroprotectants for Epilepsy.

Authors:  Nan Yang; Qi-Wen Guan; Fang-Hui Chen; Qin-Xuan Xia; Xi-Xi Yin; Hong-Hao Zhou; Xiao-Yuan Mao
Journal:  Oxid Med Cell Longev       Date:  2020-11-25       Impact factor: 6.543

Review 8.  Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype.

Authors:  Cristina Ferreira Almeida; Natércia Teixeira; Georgina Correia-da-Silva; Cristina Amaral
Journal:  Molecules       Date:  2021-12-28       Impact factor: 4.411

9.  Tunneling nanotubes, TNT, communicate glioblastoma with surrounding non-tumor astrocytes to adapt them to hypoxic and metabolic tumor conditions.

Authors:  Silvana Valdebenito; Shaily Malik; Ross Luu; Olivier Loudig; Megan Mitchell; George Okafo; Krishna Bhat; Brendan Prideaux; Eliseo A Eugenin
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

Review 10.  Drug Delivery Strategies for Curcumin and Other Natural Nrf2 Modulators of Oxidative Stress-Related Diseases.

Authors:  Nina Katarina Grilc; Matej Sova; Julijana Kristl
Journal:  Pharmaceutics       Date:  2021-12-12       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.